Remote Opioid Monitoring Act of 2025
- Bill Number
- H.R. 2404
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-27: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-04-06T10:53:25Z
AI-Generated Summary
Purpose
The Remote Opioid Monitoring Act of 2025 aims to evaluate the impact of remote monitoring technologies—such as wearable devices or apps that track health metrics from afar—on people prescribed opioids. The goal is to gather evidence on its effectiveness in improving patient outcomes, reducing costs, and addressing the opioid crisis through informed policy recommendations.
Key Provisions
- Study Requirement: The Comptroller General of the United States (head of the Government Accountability Office, an independent agency that audits federal programs) must conduct a study on remote monitoring for opioid-prescribed individuals.
- Timeline: The study must be completed and a report submitted within 18 months of the bill's enactment.
- Report Recipients: The report goes to the House Committee on Energy and Commerce, and the Senate Committees on Health, Education, Labor, and Pensions, and Finance.
- Report Contents:
- An evaluation of scientific studies on remote monitoring's effectiveness (efficacy), effects on patient health (outcomes), and potential reductions in healthcare expenses, compared to patients not using such monitoring.
- Data on how commonly remote monitoring is used for opioid patients in the U.S. and internationally.
- Suggestions for enhancing access, availability, and insurance coverage of remote monitoring, including potential updates to federal health programs like Medicare and Medicaid (defined as programs under the Social Security Act that provide healthcare to seniors, low-income individuals, and others). It may also identify specific patient groups (cohorts) who could benefit most, such as those at high risk of addiction or overdose.
Significant Changes to Existing Law
This bill introduces no direct amendments to current laws. Instead, it creates a one-time mandate for a federal study, which could indirectly influence future regulations or funding for healthcare technologies without altering statutes immediately.
Potential Impacts
- On Government Agencies: The Government Accountability Office will expend resources on the study, potentially leading to policy changes for agencies like the Centers for Medicare & Medicaid Services (CMS), which administer federal health programs. This could result in expanded coverage for remote monitoring tools.
- On Citizens: People prescribed opioids may gain better access to monitoring tools, improving safety and treatment adherence, especially for chronic pain or post-surgery patients. It could help reduce opioid misuse and overdoses, benefiting public health amid the opioid epidemic.
- On International Relations: Minimal direct impact, though the study includes international comparisons, which might inform U.S. adoption of global best practices without affecting diplomacy.
Main Stakeholders Affected
- Patients Prescribed Opioids: Primary beneficiaries or subjects of the study, including those with chronic pain, post-surgical needs, or addiction risks.
- Healthcare Providers and Insurers: Doctors, hospitals, and private insurers could see shifts in treatment protocols and reimbursement for remote monitoring.
- Federal Government Entities: Government Accountability Office (conducting the study), congressional committees (receiving the report), and federal health programs (potentially modified based on recommendations).
- Technology Developers: Companies creating remote monitoring devices may experience increased demand or regulatory guidance.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill raises no immediate constitutional concerns, as it involves non-binding recommendations rather than enforceable mandates on individuals. It aligns with existing federal authority to study public health issues under the Social Security Act.
- Constitutional: No privacy or due process issues are directly implicated, though future implementations of recommendations could require balancing patient data security with health monitoring (e.g., under HIPAA privacy rules for medical information).
- Political: As a bipartisan bill (introduced by Rep. Balderson and Rep. Kelly), it supports ongoing efforts to combat the opioid crisis without partisan controversy. The study's findings could influence future legislation on telehealth and drug policy, potentially bridging divides on healthcare spending.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Balderson, Troy [R-OH-12]
Cosponsors (1)
Recent Actions
- 2025-03-27: Referred to the House Committee on Energy and Commerce.
- 2025-03-27: Introduced in House
- 2025-03-27: Introduced in House
Bill Versions
- Remote Opioid Monitoring Act of 2025 — issued 2025-03-27 — PDF (3 pages)